Understanding the Action Mechanisms of Metformin in the Gastrointestinal Tract

Overview

Journal Front Pharmacol

Date 2024 Apr 15

PMID 38617792

Authors

Meihui Cheng

Lili Ren

Xianxian Jia

Jianwei Wang

Bin Cong

Affiliations

Soon will be listed here.

Abstract

Metformin is the initial medication recommended for the treatment of type 2 diabetes mellitus (T2DM). In addition to diabetes treatment, the function of metformin also can be anti-aging, antiviral, and anti-inflammatory. Nevertheless, further exploration is required to fully understand its mode of operation. Historically, the liver has been acknowledged as the main location where metformin reduces glucose levels, however, there is increasing evidence suggesting that the gastrointestinal tract also plays a significant role in its action. In the gastrointestinal tract, metformin effects glucose uptake and absorption, increases glucagon-like peptide-1 (GLP-1) secretion, alters the composition and structure of the gut microbiota, and modulates the immune response. However, the side effects of it cannot be ignored such as gastrointestinal distress in patients. This review outlines the impact of metformin on the digestive system and explores potential explanations for variations in metformin effectiveness and adverse effects like gastrointestinal discomfort.

Citing Articles

Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review.

Dhieb D, Mustafa D, Hassiba M, Alasmar M, Elsayed M, Musa A Biomedicines. 2025; 13(2).

PMID: 40002860 PMC: 11853021. DOI: 10.3390/biomedicines13020447.

Aerobic Exercise and Metformin: A Dual Approach to Enhancing Glycemic Maintenance in Type 2 Diabetes Mellitus.

Eslami Z, Roshandel G, Mirghani S Chonnam Med J. 2025; 61(1):9-18.

PMID: 39958268 PMC: 11821983. DOI: 10.4068/cmj.2025.61.1.9.

Protective Role of Dietary Polyphenols in the Management and Treatment of Type 2 Diabetes Mellitus.

Martiniakova M, Sarocka A, Penzes N, Biro R, Kovacova V, Mondockova V Nutrients. 2025; 17(2).

PMID: 39861406 PMC: 11767469. DOI: 10.3390/nu17020275.

A Narrative Review of the Interplay Between Carbohydrate Intake and Diabetes Medications: Unexplored Connections and Clinical Implications.

Mphasha M, Vagiri R Int J Mol Sci. 2025; 26(2).

PMID: 39859337 PMC: 11765648. DOI: 10.3390/ijms26020624.

Meeting metformin again for the first time.

Green D Sci Adv. 2024; 10(51):eadu7436.

PMID: 39693446 PMC: 11654691. DOI: 10.1126/sciadv.adu7436.

References

Bronden A, Alber A, Rohde U, Rehfeld J, Holst J, Vilsboll T . Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2017; 102(11):4153-4162. DOI: 10.1210/jc.2017-01091. View

Tucker G, Casey C, Phillips P, Connor H, Ward J, Woods H . Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981; 12(2):235-46. PMC: 1401849. DOI: 10.1111/j.1365-2125.1981.tb01206.x. View

Green B, Irwin N, Duffy N, Gault V, Oharte F, Flatt P . Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006; 547(1-3):192-9. DOI: 10.1016/j.ejphar.2006.07.043. View

Wilcock C, Bailey C . Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol. 1991; 43(2):120-1. DOI: 10.1111/j.2042-7158.1991.tb06645.x. View

Gambineri A, Tomassoni F, Ibarra Gasparini D, Di Rocco A, Mantovani V, Pagotto U . Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2010; 95(10):E204-8. DOI: 10.1210/jc.2010-0145. View

de Jager J, Kooy A, Lehert P, Wulffele M, van der Kolk J, Bets D . Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010; 340:c2181. PMC: 2874129. DOI: 10.1136/bmj.c2181. View

Hinke S, Kuhn-Wache K, Hoffmann T, Pederson R, McIntosh C, Demuth H . Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun. 2002; 291(5):1302-8. DOI: 10.1006/bbrc.2002.6607. View

Zhou K, Donnelly L, Kimber C, Donnan P, Doney A, Leese G . Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009; 58(6):1434-9. PMC: 2682689. DOI: 10.2337/db08-0896. View

Thakkar B, Aronis K, Vamvini M, Shields K, Mantzoros C . Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013; 62(7):922-34. DOI: 10.1016/j.metabol.2013.01.014. View

10.

Vasamsetti S, Karnewar S, Kanugula A, Thatipalli A, Kumar J, Kotamraju S . Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015; 64(6):2028-41. DOI: 10.2337/db14-1225. View

11.

Morita Y, Nogami M, Sakaguchi K, Okada Y, Hirota Y, Sugawara K . Enhanced Release of Glucose Into the Intraluminal Space of the Intestine Associated With Metformin Treatment as Revealed by [F]Fluorodeoxyglucose PET-MRI. Diabetes Care. 2020; 43(8):1796-1802. DOI: 10.2337/dc20-0093. View

12.

Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D . Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2011; 61(1):187-96. PMC: 3237647. DOI: 10.2337/db11-1029. View

13.

Liu Z, Liao W, Zhang Z, Sun R, Luo Y, Chen Q . Metformin Affects Gut Microbiota Composition and Diversity Associated with Amelioration of Dextran Sulfate Sodium-Induced Colitis in Mice. Front Pharmacol. 2021; 12:640347. PMC: 8191634. DOI: 10.3389/fphar.2021.640347. View

14.

Chen C, You L, Huang Q, Fu X, Zhang B, Liu R . Modulation of gut microbiota by mulberry fruit polysaccharide treatment of obese diabetic db/db mice. Food Funct. 2018; 9(7):3732-3742. DOI: 10.1039/c7fo01346a. View

15.

Wculek S, Dunphy G, Heras-Murillo I, Mastrangelo A, Sancho D . Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol. 2021; 19(3):384-408. PMC: 8891297. DOI: 10.1038/s41423-021-00791-9. View

16.

Chambers E, Viardot A, Psichas A, Morrison D, Murphy K, Zac-Varghese S . Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2014; 64(11):1744-54. PMC: 4680171. DOI: 10.1136/gutjnl-2014-307913. View

17.

Ryan P, Patterson E, Carafa I, Mandal R, Wishart D, Dinan T . Metformin and Dipeptidyl Peptidase-4 Inhibitor Differentially Modulate the Intestinal Microbiota and Plasma Metabolome of Metabolically Dysfunctional Mice. Can J Diabetes. 2019; 44(2):146-155.e2. DOI: 10.1016/j.jcjd.2019.05.008. View

18.

Lalau J, Al-Salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin M . Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 2020; 47(5):101216. PMC: 7832745. DOI: 10.1016/j.diabet.2020.101216. View

19.

DAlessio D . Is GLP-1 a hormone: Whether and When?. J Diabetes Investig. 2016; 7 Suppl 1:50-5. PMC: 4854505. DOI: 10.1111/jdi.12466. View

20.

Hiel S, Gianfrancesco M, Rodriguez J, Portheault D, Leyrolle Q, Bindels L . Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial. Clin Nutr. 2020; 39(12):3618-3628. DOI: 10.1016/j.clnu.2020.04.005. View